Gordon Reid of Goodreid Investment Counsel highlights Eli Lilly, Mercado Libre and Texas Instruments as his U.S. equity picks. He says headline indexes sit near record highs, but the rally is narrow: 59% of stocks trade more than 20% below their all-time highs and 26% more than 40% below. He argues corporate earnings are strong, with year-over-year growth of 25% or more expected in the final quarter of 2026 and profit margins near 15%, while consumers are squeezed by inflation, the Iran war, tariffs and high Fed rates. The picks rest on Eli Lilly's GLP-1 opportunity, with a total addressable market estimated above US$100 billion, Mercado Libre's position as a Latin American e-commerce leader, and Texas Instruments' more stable analog chip business. Picks from October 21, 2025 show Elevance Health gaining 22% (24% total return), Rocket Companies falling 34%, and an average total return of -0.3%.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Gordon Reid Top Picks for Oct . 21 , 2026 – BNN Bloomberg
Read the original on bnnbloomberg.ca ↗
Keywords
Eli LillyTexas InstrumentsMercado Libreinflation
Open a keyword to see other news on the same topic.
Related news
- Tesla Will Make Millions of Optimus Robots. Texas Instruments Can Get Paid on Every One
Tesla has started producing its humanoid Optimus robots on high-volume lines in Fremont, while Texas Instruments (TXN) said its chip content per humanoid robot runs from $500 to $1,000, without naming Tesla or Optimus as a customer. Tesla disclosed no unit volumes; Musk estimated about a million units per line but said reaching 20,000 units a week would probably take at least a year. Using those figures, the article estimates TI's annual robot-related chip content at roughly $500 million to $1 billion if it won every socket, compared with $6.055 billion in revenue booked last quarter. The author argues TI's robotics case does not depend on Tesla, but it would weaken if timelines slip and industry volumes stay small for years.
- Texas Instruments Q3 earnings beat estimates on chip demand
Texas Instruments (TXN) reported third-quarter results on 21 October 2026 that beat forecasts, with diluted EPS of $2.62 against a consensus of $2.41 and revenue of $6.06bn, according to GuruFocus citing an 8-K filing. Shares closed at $288.39, up 0.32%, on trading volume 2.31 times the 20-day average. The earnings call pointed to broad strength, with industrial revenue at a record and the data centre segment growing 95%. Compared with the third quarter of 2025, revenue of $4.74bn implies growth of roughly 28%, and diluted EPS of $1.48 implies a rise of around 77%. Revenue has risen sequentially since early 2024, and the most recent filed quarter, covering April to June 2026, showed revenue of $5.46bn in a 10-Q filed on 24 July 2026.
- Trump trade adviser defends tariffs , touts Texas Instrument investment in new Lehi plant
U.S. Trade Representative Jamieson Greer, a top trade adviser to President Donald Trump, toured Texas Instruments' new $11 billion semiconductor plant in Lehi and defended the administration's tariffs. He argued that tariffs protect U.S. manufacturing from unfair foreign subsidies and dumping, and aim to create better-paying jobs. Greer rejected the idea that tariffs drove recent inflation, noting consumer prices rose 3.7% annually last month and that beef, oranges and bananas are not tariffed. However, a New York Federal Reserve study found prices of 67 tariffed goods rose 2.9% as of February, while they would have fallen nearly 1% without tariffs. The plant is expected to create 800 high-paying jobs and strengthen the domestic supply chain for critical components.
- Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
The article compares revenue growth at Bristol Myers Squibb and Eli Lilly. Lilly's growth is driven by GLP-1 drugs: Mounjaro brought in $9.9 billion worldwide in Q2 (up 91% year over year), Zepbound $4.9 billion in U.S. sales, and the oral Foundayo, launched in April 2026, $98 million in its first quarter. Bristol Myers Squibb (BMY) has steadier revenue, with no GLP-1 drug on the market and reliance on Eliquis and Opdivo, and its growth portfolio made up 58% of Q2 revenue. The article notes Bristol Myers Squibb trades at about 9.4 times forward earnings versus almost 25 times for Lilly, and says Lilly's two main products account for nearly two-thirds of quarterly sales, a concentration and pricing risk to its growth. Both companies report third-quarter results on Oct. 29.
- Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
Novo Nordisk presented a post hoc analysis of a Phase 3 CagriSema trial at The Menopause Society meeting: after 68 weeks, 2,309 women lost almost 25% of body weight on average, versus 3% on placebo. Among 1,902 women with menopause-related overweight or obesity, mean loss ranged from 23% to nearly 27%, while placebo averaged 2%. These results beat or match Wegovy (just under 15%) and Zepbound (nearly 21%), though in the head-to-head Redefine 4 trial, tirzepatide, Zepbound's molecule, showed similar or slightly higher efficacy, nearly 26% at the maximum dose. The author argues CagriSema is unlikely to win back market share from Eli Lilly, so investors should watch Novo's other pipeline programs, and notes the figures assume patients use the drug as directed.
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
U.S. stocks rose Monday as investors bought chip stocks after last week's sell-off, and the iShares Semiconductor ETF (SOXX) was on track to snap a nine-session losing streak, its worst since May 2006. The bounce was tepid: the Nasdaq rose 1%, while CoreWeave turned negative and fell to a new low for the year below $60 per share. Oil rose about $2 to around $103 per barrel, lifting inflation worries and pushing Treasury yields higher. Bank of America raised its price target on Eli Lilly to $1,397 from $1,341 after a physician survey suggested oral GLP-1 pills and Medicare coverage are expanding the obesity drug market, with Foundayo at 27% of U.S. oral GLP-1 new starts. Lilly reports Q3 earnings on Oct. 29.
Related markets
Latest news
- Not Stocks or Real Estate, This Is the First Group of Shares to Benefit as Interest Rates Fall
Mr. Đỗ Bảo Ngọc, General Director of Kirin Securities (CSI), says falling interest rates will affect sectors differently. Construction and infrastructure construction stand to benefit directly from lower borrowing costs and better disbursement progress, while real estate and securities benefit indirectly and later. Securities shares are notable because they fell sharply during the rate-hike period, but the gains become clear only when liquidity improves and capital flows back. Banks may face pressure on net interest margin (NIM) when they cut lending rates to support businesses, although overall bank profits do not necessarily fall by the same amount.
- A High-Profile Stock Faces Simultaneous Net Selling by 16 Funds
HPG remained on the net-selling list for a fourth consecutive month, with 16 funds net selling about 8.3 million shares in September 2026, mainly from PYN Elite, DCDS, DCDE and LVF, according to FiinGroup. Banking was the only sector net bought above VND 1,000 billion (about VND 1,034 billion), while real estate saw net selling of about VND 2,212 billion and financial services about VND 1,347 billion. Funds recorded net outflows of VND 8,600 billion in Q3, the seventh consecutive quarter of withdrawals, bringing nine-month outflows to nearly VND 31,700 billion, up 34.2% year on year. The average return of equity funds fell 6% in Q3, with 87 of 88 funds posting negative results.
- Gloomy market: investor cash on securities accounts falls to a three-year low
Investor deposits at securities companies were estimated at about VND 72,000 billion at end-Q3 2026, down over 12% from the previous quarter and the lowest since end-Q2 2023, marking the second straight quarterly decline. Compared with a record of about VND 131,000 billion at end-Q3 2025, balances have shrunk by about VND 59,000 billion, or roughly 45%. The decline is broad: VPS still leads with VND 12,834 billion but fell 11% in the quarter, TCBS dropped more than 31% to VND 6,225 billion, and SSI stands at VND 5,572 billion, while Vietcap rose over 122% to VND 5,067 billion. Average matched trading value on HoSE was only about VND 14,000 billion per session, down about 23% from the previous quarter and 63% year on year, reflecting more cautious investor sentiment.
- Q3 2026 securities firm update: big names report "backward" profits, two losses of hundreds of billions emerge in the sector
Based on 81 securities firms that have reported, total pre-tax profit in Q3 2026 reached about VND 11,000 billion, down 43% year on year, with 58 firms in profit and 23 reporting losses. TCBS led with VND 2,152 billion, up over 6% and its highest level in company history, while SSI earned VND 1,295 billion (down 27%) and VPS VND 1,119 billion (down nearly 20%). Meanwhile, HDS's quarterly profit more than tripled year on year, ABS rose 552%, and VIX's profit plunged nearly 94% to about VND 192 billion. Nine-month cumulative results stayed strong for many, including TCBS up nearly 13%, SSI up 8% and VPS up nearly 27%.
- A Key Indicator Hints at the Possibility of VN-Index Entering a “New Wave”
The State Bank of Vietnam on October 18 asked credit institutions to cut lending rates for priority sectors, and several commercial banks have also cut deposit and lending rates, raising hopes that capital costs will ease. However, Mr. Đỗ Bảo Ngọc, General Director of Kirin Securities (CSI), says a single rate cut is not enough to move money significantly, and the downtrend must be sustained over the medium term. Liquidity is the most important indicator to watch; continued rate cuts alongside stronger trading value in Q4 or early Q1 next year would be a clearer sign that money is returning. Some experts say a sustained uptrend requires liquidity above VND 20,000 billion per session and large-cap stocks leading, conditions not yet met even though P/E and P/B have fallen to low levels. The article argues investors need not wait for VN-Index to break out to find opportunities, but a sharp stock decline alone is not reason enough to buy.
- A Vietnamese Woman Has Just Added More Than VND 4,000 Billion to Her Fortune
Phạm Thu Hương, wife of billionaire Phạm Nhật Vượng, saw her fortune rise nearly USD 160 million (about VND 4,150 billion), or 4.05%, on October 22, reaching about USD 4.1 billion according to Forbes. She ranks 1,035th among the world’s billionaires and is Vietnam’s third-richest person. The gain followed a strong session for Vingroup’s VIC shares, which rose more than 4% to VND 232,900 per share, their second straight gain after hitting the ceiling price on October 21. VIC is up nearly 40% since the start of 2026, with a market capitalization of VND 1.8 million billion. Phạm Nhật Vượng’s fortune is about USD 36.2 billion, up about 3.53%. Known for her low profile, Hương has been Vice Chairwoman of Vingroup’s Board since 2011 and co-founded the VinFuture Foundation with Vượng in 2020.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.